Bernd H A Rehm Selected Research

mannuronic acid

1/2020	Mannuronic Acid in Low-Risk and Intermediate-1-Risk Myelodysplastic Syndromes.
10/2019	International multicenter randomized, placebo-controlled phase III clinical trial of β-D-mannuronic acid in rheumatoid arthritis patients.
1/2019	A randomized, controlled, phase II clinical trial of β-D-mannuronic acid (M2000) in pre-surgical breast cancer patients at early stage (T1-T2).
6/2018	A phase I/II randomized, controlled, clinical trial for assessment of the efficacy and safety of β-D-mannuronic acid in rheumatoid arthritis patients.
4/2018	Oral administration effects of β-d-mannuronic acid (M2000) on Th17 and regulatory T cells in patients with ankylosing spondylitis.
4/2018	The effects of β-D-mannuronic acid (M2000), as a novel NSAID, on COX1 and COX2 activities and gene expression in ankylosing spondylitis patients and the murine monocyte/macrophage, J774 cell line.
1/2018	Evaluation of the efficacy and safety of β-d-mannuronic acid in patients with ankylosing spondylitis: A 12-week randomized, placebo-controlled, phase I/II clinical trial.
1/2017	The Potent Inhibitory Effect of β-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property on Anti-Cyclic Citrullinated Peptide Antibodies, Rheumatoid Factor and Anti-dsDNA Antibodies in Patients with Rheumatoid Arthritis.
1/2005	Novel immunosuppressive therapy by M2000 in experimental multiple sclerosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bernd H A Rehm Research Topics

Disease

13	Infections 01/2023 - 01/2012
11	Tuberculosis (Tuberculoses) 01/2022 - 12/2009
8	Neoplasms (Cancer) 01/2024 - 10/2004
5	Communicable Diseases (Infectious Diseases) 01/2024 - 01/2017
5	Bovine Tuberculosis 01/2022 - 03/2014
4	Rheumatoid Arthritis 01/2020 - 01/2017
4	Ankylosing Spondylitis 06/2018 - 01/2018
4	Inflammation (Inflammations) 04/2018 - 01/2012
4	Cystic Fibrosis (Mucoviscidosis) 09/2015 - 03/2010
3	Proteinuria 08/2005 - 01/2004
2	Q Fever (Fever, Q) 01/2024 - 09/2023
2	Persistent Infection 01/2022 - 03/2010
2	Pneumonia (Pneumonitis) 01/2022 - 12/2017
2	Ovarian Neoplasms (Ovarian Cancer) 07/2021 - 10/2020
2	Breast Neoplasms (Breast Cancer) 06/2021 - 01/2019
2	Pneumococcal Infections 09/2018 - 04/2017
2	Pain (Aches) 04/2018 - 10/2017
2	Hepatitis C 12/2017 - 12/2011
2	Starvation 02/2008 - 08/2004
2	Glomerulonephritis 08/2005 - 06/2005
2	Nephrosis 08/2005 - 01/2004
1	Human Influenza (Influenza) 02/2024
1	Fever (Fevers) 01/2024
1	Pseudomonas Infections 01/2022
1	COVID-19 01/2022
1	Paratuberculosis (Johne's Disease) 01/2022
1	Malaria 11/2021
1	Carcinoma (Carcinomatosis) 06/2021
1	Urinary Bladder Neoplasms (Bladder Cancer) 06/2021
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2020
1	Circulating Neoplastic Cells 11/2019
1	Bacterial Infections (Bacterial Infection) 01/2018
1	Meningeal Tuberculosis (Tuberculous Meningitis) 12/2017
1	Virus Diseases (Viral Diseases) 12/2011
1	Muscle Cramp (Cramp) 09/2008
1	Kidney Diseases (Kidney Disease) 08/2005
1	Nephritis 06/2005

Drug/Important Bio-Agent (IBA)

19	AntigensIBA 01/2024 - 12/2009
19	VaccinesIBA 01/2024 - 12/2011
9	mannuronic acidIBA 01/2020 - 01/2005
8	Proteins (Proteins, Gene)FDA Link 01/2024 - 12/2009
6	Subunit VaccinesIBA 01/2024 - 01/2017
5	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 04/2018 - 10/2004
4	DNA (Deoxyribonucleic Acid)IBA 07/2021 - 01/2017
4	Therapeutic UsesIBA 10/2019 - 08/2005
4	PolyestersIBA 01/2018 - 03/2014
4	AlginatesIBA 01/2017 - 06/2005
3	EpitopesIBA 01/2024 - 11/2021
3	Tuberculin (PPD)IBA 01/2022 - 04/2014
3	PolymersIBA 01/2022 - 11/2021
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 01/2012
3	Biomarkers (Surrogate Marker)IBA 07/2021 - 11/2019
2	Biopolymers (Biopolymer)IBA 01/2024 - 07/2021
2	CytokinesIBA 01/2024 - 04/2018
2	RNA (Ribonucleic Acid)IBA 10/2020 - 11/2019
2	Interleukin-6 (Interleukin 6)IBA 04/2018 - 01/2004
2	Virulence Factors (Pathogenicity Factors)IBA 09/2015 - 03/2010
2	NitrogenIBA 02/2008 - 08/2004
2	CholesterolIBA 08/2005 - 01/2004
2	CreatinineIBA 08/2005 - 01/2004
2	Antigen-Antibody Complex (Immune Complex)IBA 08/2005 - 06/2005
1	Poly I-CIBA 02/2024
1	Interleukin-12 (IL 12)IBA 01/2024
1	Cancer VaccinesIBA 12/2023
1	CRM197 (non-toxic variant of diphtheria toxin)IBA 01/2023
1	Aluminum Hydroxide (Algeldrate)FDA Link 01/2022
1	Complex MixturesIBA 07/2021
1	Tumor Biomarkers (Tumor Markers)IBA 07/2021
1	Phenobarbital (Luminal)FDA Link 06/2021
1	Protein Subunit VaccinesIBA 12/2020
1	GoldIBA 10/2020
1	MicroRNAs (MicroRNA)IBA 11/2019
1	AutoantibodiesIBA 11/2019
1	Cell-Free Nucleic AcidsIBA 11/2019
1	Carcinoembryonic AntigenIBA 01/2019
1	Interleukin-17 (Interleukin 17)IBA 04/2018
1	CarbohydratesIBA 01/2018
1	Naproxen (Naprosyn)FDA LinkGeneric 01/2018
1	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 10/2017
1	EnzymesIBA 10/2017
1	Carrier Proteins (Binding Protein)IBA 04/2017
1	Acute-Phase Proteins (Acute-Phase Protein)IBA 01/2017
1	anti-dsDNA autoantibodyIBA 01/2017
1	Rheumatoid FactorIBA 01/2017
1	Anti-Citrullinated Protein AntibodiesIBA 01/2017
1	polyhydroxybutyrateIBA 03/2014
1	BCG Vaccine FDA Link 01/2014
1	Viral AntigensIBA 12/2011
1	Polysaccharides (Glycans)IBA 03/2010
1	poly(3-hydroxyalkanoic acid) synthaseIBA 12/2009
1	Polymyxin B (Aerosporin)FDA LinkGeneric 09/2008
1	bactenecinIBA 09/2008
1	Peptides (Polypeptides)IBA 09/2008
1	indolicidinIBA 09/2008
1	Immunosuppressive Agents (Immunosuppressants)IBA 06/2005

Therapy/Procedure

4	Therapeutics 06/2021 - 01/2004
2	Oral Administration 10/2019 - 04/2018
1	Electrodes (Electrode) 10/2020
1	Aftercare (After-Treatment) 01/2019
1	Intravenous Administration 06/2005